Sumitomo Mitsui Trust Group
ADPT icon

Sumitomo Mitsui Trust Group’s Adaptive Biotechnologies ADPT Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.5M Sell
1,329,856
-265,514
-17% -$4.07M 0.02% 578
2026
Q1 		$22.1M Sell
1,595,370
-352,593
-18% -$5.62M 0.01% 609
2025
Q4 		$31.6M Sell
1,947,963
-1,702,683
-47% -$27.8M 0.02% 575
2025
Q3 		$54.6M Sell
3,650,646
-649,038
-15% -$7.91M 0.03% 447
2025
Q2 		$50.1M Sell
4,299,684
-1,786,006
-29% -$16.2M 0.03% 454
2025
Q1 		$45.2M Sell
6,085,690
-747,447
-11% -$5.74M 0.03% 465
2024
Q4 		$41M Sell
6,833,137
-900,747
-12% -$4.97M 0.03% 506
2024
Q3 		$39.6M Buy
7,733,884
+834,253
+12% +$3.63M 0.03% 510
2024
Q2 		$25M Buy
6,899,631
+722,924
+12% +$2.29M 0.02% 598
2024
Q1 		$19.8M Sell
6,176,707
-334,952
-5% -$1.3M 0.01% 709
2023
Q4 		$31.9M Sell
6,511,659
-59,280
-0.9% -$270K 0.02% 604
2023
Q3 		$35.8M Buy
6,570,939
+186,892
+3% +$1.24M 0.03% 546
2023
Q2 		$42.8M Buy
6,384,047
+1,061,511
+20% +$7.89M 0.03% 518
2023
Q1 		$47M Sell
5,322,536
-29,779
-0.6% -$263K 0.04% 517
2022
Q4 		$40.9M Buy
5,352,315
+514,124
+11% +$4M 0.03% 551
2022
Q3 		$34.4M Buy
4,838,191
+219,792
+5% +$2.07M 0.03% 582
2022
Q2 		$37.4M Buy
4,618,399
+486,339
+12% +$4.28M 0.03% 598
2022
Q1 		$57.4M Buy
4,132,060
+936,614
+29% +$14.7M 0.04% 497
2021
Q4 		$89.7M Buy
3,195,446
+1,133,445
+55% +$34.7M 0.05% 373
2021
Q3 		$70.1M Buy
2,062,001
+238,060
+13% +$8.61M 0.04% 442
2021
Q2 		$74.5M Buy
1,823,941
+1,394,838
+325% +$54.2M 0.04% 429
2021
Q1 		$17.3M Buy
429,103
+187,956
+78% +$10.2M 0.01% 731
2020
Q4 		$14.3M Buy
241,147
+29,084
+14% +$1.5M 0.01% 748
2020
Q3 		$10.3M Buy
212,063
+20,946
+11% +$880K 0.01% 756
2020
Q2 		$9.25M Buy
191,117
+169,517
+785% +$6.18M 0.01% 749
2020
Q1 		$600K Buy
+21,600
New +$602K ﹤0.01% 984

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Sumitomo Mitsui Trust Group's ADPT Position: Q2 2026 in Review

Sumitomo Mitsui Trust Group reduced its Adaptive Biotechnologies (ADPT) stake by 17% in Q2 2026, selling an estimated $4.07M and leaving 1,329,856 shares worth $28.5M. The position accounts for 0.02% of the portfolio, ranked #578.

Sumitomo Mitsui Trust Group first reported a position in ADPT in Q1 2020 and has held it in 26 quarters since. The position peaked at $89.7M in Q4 2021. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Sumitomo Mitsui Trust Group held 1,329,856 shares of Adaptive Biotechnologies worth $28.5M as of Q2 2026.
  • Sumitomo Mitsui Trust Group sold 265,514 Adaptive Biotechnologies shares in Q2 2026, an estimated $4.07M.
  • Adaptive Biotechnologies made up 0.02% of Sumitomo Mitsui Trust Group's portfolio in Q2 2026, its #578 holding.
  • Sumitomo Mitsui Trust Group first reported a position in Adaptive Biotechnologies in Q1 2020 and has held it in 26 quarters since.
  • Sumitomo Mitsui Trust Group's Adaptive Biotechnologies position peaked at $89.7M in Q4 2021.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q2 2026, filed 30 Jul 2026.